Jeff Aronin: Weizmann Leadership Award Recipient

At a time when matters of healthcare and disease seem to be consistently in the public zeitgeist, it can appear as though there is a lot being talked about, but not a lot being done. We need innovators and creators to treat disease and ease suffering. Fortunately, there are people in the world like Jeff Aronin who are willing to push forward and make advancements toward humanity’s well-being. Despite the challenges and obstacles, Aronin has become one of the pioneering innovators the field so desperately needs.


Jeff Aronin, the 2017 Weizmann Leadership Award recipient and CEO of Paragon Biosciences, has two decades of experience in developing companies specializing in healthcare innovation. The combination of his entrepreneurial instinct and his knowledge in the areas of drug development, rare disease, and complex science have allowed him to achieve a remarkable amount of success in the bioscience sector. He facilitates the cooperation and teamwork of scientists and business executives to create and discover new drugs and therapies that will ease suffering and enhance the lives of often neglected patients. He and his teams have successfully obtained 13 Novel Drug Approvals through the FDA, and he serves as a mentor for up-and-coming entrepreneurs (Chicago.BlueSkyInnovation).


Along with being an experienced and accomplished innovation and business expert, Jeff Aronin is known for his connections and focus on people ( He has been described by colleagues and associates as being “enthusiastic” about developing solutions and “passionate” about patient care. He has a deep-rooted commitment to making people’s lives healthier and happier. Patients are not just patients to him, they are whole human beings with lives and loved ones. It is this kind of compassionate approach to research and innovation that keeps the work Aronin does focus on the people he serves. He has a “big heart”, and it is apparent to everyone around him.


Leave a Reply

Your email address will not be published. Required fields are marked *